Bristol-Myers Squibb Company

NYSE: BMY
$49.41
+$0.39 (+0.8%)
Closing Price on September 20, 2024

BMY Articles

The top analyst upgrades, downgrades and other research calls from Wednesday include Chevron, Chipotle Mexican Grill, Exxon Mobil, Goldman Sachs, GoPro, IBM, Merck, Petrobras, UnitedHealth, Visa and...
The top analyst upgrades, downgrades and other research calls from Monday include Adobe, Apple, Bristol-Myers, Citigroup, Ford, Groupon, Phillips 66 and United Rentals.
The September 29 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
The September 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The top analyst upgrades, downgrades and other research calls from Friday include AbbVie, Bristol-Myers, Eli Lilly, First Solar, Generac, Oracle, Sirius XM, Southwest and Wendy's.
The August 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
Usually when a clinical study is stopped it spells disaster for the company performing the study, but in this case Bristol-Myers Squibb is bucking that trend and investors are thrilled.
The August 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks dropped.
The July 31 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks increased.
The July 14 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks decreased.
Major pharmaceutical companies have posted a relatively positive year so far. Currently, Johnson & Johnson (NYSE: JNJ) is leading the pack with Eli Lilly and Co. (NYSE: LLY) in a close second....
The June 30 short interest data have been compared with the previous figures, and short interest moves in these selected pharmaceutical stocks were mixed.
The June 15 short interest data have been compared with the previous figures, and short interest in most of these selected pharmaceutical stocks shrank.
These are the top 20 stock buybacks in dollars spent during the first quarter of 2017 of all S&P 500 companies.
A series of new reports from Jefferies focus on some of the top stocks in the pharmaceutical and biotech arenas. Almost all these stocks have data that could send shares measurably higher.